TMCnet News
Research and Markets: Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2012DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/8938cv/islet_cell) has announced the addition of Global Markets Direct's new report "Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Islet Cell Carcinoma (Insulinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic devlopment for Islet Cell Carcinoma (Insulinoma). Islet Cell Carcinoma (Insulinoma) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Islet Cell Carcinoma (Insulinoma). - A review of the Islet Cell Carcinoma (Insulinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Islet Cell Carcinoma (Insulinoma) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. For more information visit http://www.researchandmarkets.com/research/8938cv/islet_cell Source (News - Alert): Global Markets Direct |
